MetaCap

C4 Therapeutics (CCCC) vs SL Science (SLBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

C4 Therapeutics (CCCC) has outperformed SL Science (SLBT) over the past year, gaining 1.6% versus a loss of 94.8%. C4 Therapeutics is the larger company by market cap ($325.7 million vs $308.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CCCC+1.64%SLBT-94.76%
+101%-2%-104%
Nov 21, 20251 yearNov 20, 2026
CCCC-30.14%SLBT-94.51%
+33%-34%-101%
Feb 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CCCC versus SLBT key metrics
MetricCCCCSLBT
Share price$2.48$0.55
Market cap$325.67M$308.42M
1-day change+1.64%-3.36%
YTD return+29.84%-94.78%
1-year return+1.64%-94.76%
5-year return-93.23%—
EPS (TTM)$-0.63$0.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$35.95M—
Revenue growth (YoY)+1.02%—
Net income (latest FY)$-104.99M—
Operating margin-320.53%—
Net margin-292.08%—
52-week high$5.17$14.50
52-week low$1.69$0.51
Distance from 52-week high-52.03%-96.21%
Analyst consensusstrong_buy—
Avg. price target upside+404.03%—
Average volume2.57M67.66K
Shares outstanding131.32M560.76M
Employees10414
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CCCC has outperformed SLBT by 96.4 percentage points over the past year.

About C4 Therapeutics

CCCC stock →

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees

About SL Science

SLBT stock →

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees

CCCC vs SLBT FAQ

Which is bigger, C4 Therapeutics or SL Science?

C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $308.42M for SL Science (SLBT).

Which stock has performed better over the past year, CCCC or SLBT?

CCCC returned +1.64% over the past 12 months, compared with -94.76% for SLBT (price return, excluding dividends). Past performance does not predict future results.

Are C4 Therapeutics and SL Science in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons